[1] |
ZHANG Jingchen, LI Xin, LI Jiangtao, LI Haiping, CHEN Yanli, NIU Bing, QI Chuanchuan, YE Beibei.
LINC02163 targeting miR-338-3p affects proliferation, invasion and migration of breast cancer cells
[J]. China Oncology, 2022, 32(9): 818-826.
|
[2] |
XIAO Yuling, ZHU Xiuzhi, JIANG Yizhou, SHAO Zhimin.
New research advances and future prospect in precision treatment of triple-negative breast cancer
[J]. China Oncology, 2022, 32(8): 669-679.
|
[3] |
QIU Pengfei, WANG Yongsheng.
Precise regional management of breast cancer in the sentinel lymph node era: evolution and prospect
[J]. China Oncology, 2022, 32(8): 680-687.
|
[4] |
ZHANG Yu, LIU Qiang.
Advances of liquid biopsy in precision treatment of breast cancer
[J]. China Oncology, 2022, 32(8): 688-697.
|
[5] |
ZHOU Wenbin, XIE Hui, DING Qiang, WANG Shui.
New research progress of microwave ablation in the local precise treatment of early-stage breast cancer: the prospect of combined immunotherapy is promising
[J]. China Oncology, 2022, 32(8): 698-704.
|
[6] |
LIU Yiming, FAN Lei, MO Miao, SHAO Zhimin, YU Keda.
Factors-associated with short-term effect and long-term survival of ovarian function suppression in estrogen receptor positive breast cancer: a retrospective analysis
[J]. China Oncology, 2022, 32(8): 705-711.
|
[7] |
XIAO Jialong, MO Miao, ZHOU Changming, WANG Zezhou, SHEN Jie, YUAN Jing, YU Keda, LIU Guangyu, WU Jiong, SHEN Zhenzhou, SHAO Zhimin, ZHENG Ying.
The effect of the interaction between body mass index and age on the prognosis of breast cancer
[J]. China Oncology, 2022, 32(8): 719-726.
|
[8] |
CHEN Anli, SHEN Haoyuan, YANG Shixiong, DENG Chunyan, HU Chaohua, LIU Hanzhong, WANG Shu, QIAN Fang.
Predictive value of plasma long non-coding RNA H19 in neoadjuvant therapy for breast cancer
[J]. China Oncology, 2022, 32(8): 727-735.
|
[9] |
LIU Qiang, FANG Yi, WANG Jing.
Application progress of single-cell sequencing technology in breast cancer research
[J]. China Oncology, 2022, 32(7): 635-642.
|
[10] |
QIAN Yao, LIU Feng.
Research progress and prospects of neoadjuvant endocrine therapy for breast cancer
[J]. China Oncology, 2022, 32(7): 643-649.
|
[11] |
JIA Xiaoqing, SUN Xiaoyin, JIANG Beiqi, MEI Zhangyi, FU Yun, ZHUANG Zhigang.
Neddylation modification regulates lamin B1 expression in breast cancer
[J]. China Oncology, 2022, 32(6): 535-541.
|
[12] |
LIU Jianlan, CHEN Daishi, HU Hong, ZHOU Dongxian, HU Jintao.
Predictors of response to neoadjuvant treatment and changes to HER2 status in HER2-positive invasive breast cancer
[J]. China Oncology, 2022, 32(5): 417-426.
|
[13] |
ZHANG Qian, FANG Xiaoyan, LIU Juan, LIU Jin, CHENG Leilei, SUN Jing.
Study on the safety of simultaneous integrated boost and the importance of cardiac substructural dose assessment of hypofractionated radiotherapy after early left breast cancer breast-conserving surgery
[J]. China Oncology, 2022, 32(5): 427-435.
|
[14] |
XU Bingqi, ZHANG Guoqiang.
Advances in the diagnosis of pathological response by a second biopsy in breast cancer neoadjuvant therapy and their clinical significance
[J]. China Oncology, 2022, 32(4): 335-342.
|
[15] |
The Society of Breast Cancer, China Anti-Cancer Association.
Screening and early diagnosis of breast cancer in China: a practice guideline
[J]. China Oncology, 2022, 32(4): 363-372.
|